US FDA Authorizes Pfizer's Paxlovid, In The Nick Of Time

With the US Food and Drug Administration granting emergency use authorization to Pfizer Inc.'s oral COVID-19 therapy Paxlovid, the pharma is working on ways to increase awareness of the new treatment option and ensure patients can get quick access to therapy.

The EUA was granted on 22 December, amid increasing concern about the Omicron variant. It covers use in patients 12 years of age and older weighing at least 40kg for the treatment of mild-to-moderate COVID-19 in patients at high risk of progression to severe disease, including hospitalization or death